Education
About Us
Working with TipRanks
Follow Us
Hunter Smith Insider Profile
4 Followers
Hunter Smith, Director at Genesee & Wyoming, holds 109.93K shares in Rhythm Pharmaceuticals (Ticker: RYTM), holds 0.00 shares in Genesee & Wyoming (Ticker: GWR), holds ― shares in Spyre Therapeutics (Ticker: SYRE).
Hunter Smith Genesee & Wyoming (GWR)Director
Genesee & Wyoming (GWR)
Director
Not Ranked
Hunter Smith has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Hunter Smith holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Hunter Smith
Hunter Smith's Trading History
Genesee & Wyoming
Dec 30, 2019
―
Uninformative Sell
1.32M
$0.00
Rhythm Pharmaceuticals
Feb 19, 2025
CFO
Uninformative Buy
248.59K
$5.58M
Spyre Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Hunter Smith's performance on stock
You May Also Like
Hunter Smith insider profile FAQ
What is the percentage of profitable transactions made by Hunter Smith?
The percentage of profitable transactions made by Hunter Smith is ―.
What is the average return per transaction made by Hunter Smith?
The average return per transaction made by Hunter Smith is ―.
What stocks does Hunter Smith hold?
Hunter Smith holds: GWR, RYTM, SYRE stocks.
What was Hunter Smith’s latest transaction?
Hunter Smith latest transaction was an Uninformative Buy of $248.59K.
What was Hunter Smith's most profitable transaction?
Hunter Smith’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Hunter Smith's role in Genesee & Wyoming?
Hunter Smith's role in Genesee & Wyoming is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.